Skip to main content
Changchun Bcht Biotechnology Co. logo

Changchun Bcht Biotechnology Co. — Investor Relations & Filings

Ticker · 688276 ISIN · CNE100005XY6 LEI · 8368000E14LIZR0C4328 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 511 across all filing types
Latest filing 2023-09-01 Interim / Quarterly Rep…
Country CN China
Listing Shanghai Stock Exchange 688276

About Changchun Bcht Biotechnology Co.

http://www.bchtpharm.com

Changchun BCHT Biotechnology Co. is a biopharmaceutical enterprise focused on the research, development, production, and marketing of human vaccines. The company specializes in preventing infectious diseases through innovative biological products. Its primary product portfolio includes the Varicella Vaccine (Live), which maintains a significant market presence, and the Influenza Vaccine (Live, Nasal, Freeze-dried). Additionally, the company produces the Rabies Vaccine for human use and has expanded its pipeline to include a Herpes Zoster vaccine. BCHT Biotechnology emphasizes technological innovation, utilizing advanced platforms for viral culture and purification to ensure product safety and efficacy. The company operates large-scale manufacturing facilities designed to meet international quality standards, aiming to address public health needs through a diverse range of immunization solutions.

Recent filings

Filing Released Lang Actions
中信证券股份有限公司关于长春百克生物科技股份公司2023年半年度持续督导跟踪报告
Interim / Quarterly Report Classification · 95% confidence The document is titled as a "2023年半年度持续督导跟踪报告" which translates to "2023 Semi-Annual Continuous Supervision Follow-up Report". It is issued by the sponsor institution (中信证券股份有限公司) responsible for ongoing supervision of the company after its IPO on the STAR Market. The content includes detailed descriptions of supervision activities, compliance with regulations, risk disclosures, financial data for the first half of 2023, R&D progress, and use of raised funds. The document contains substantive financial data and analysis for the half-year period, including income, profit, cash flow, and R&D expenditures. It is clearly a comprehensive report covering a period shorter than a full fiscal year (half-year). This matches the definition of an Interim / Quarterly Report (IR). It is not a mere announcement or certification, but a full report with detailed financial and operational information. Therefore, the correct classification is IR with high confidence. H1 2023
2023-09-01 Chinese
国泰君安证券股份有限公司关于长春百克生物科技股份公司2022年限制性股票激励计划预留授予及作废部分预留限制性股票事项独立财务顾问报告
Capital/Financing Update Classification · 95% confidence The document is an Independent Financial Advisor Report related to a 2022 restricted stock incentive plan for Changchun Baike Biotechnology Co., Ltd. It details the reserved grant and cancellation of reserved restricted stocks, including approval processes, grant conditions, pricing adjustments, and the impact of cancellations. The document includes detailed financial and legal analysis related to the stock incentive plan, approvals by the board and shareholders, and compliance with relevant laws and regulations. It is not a general annual report, earnings release, or a simple announcement but a specialized advisory report on stock incentive matters. This type of document fits best under the category of Capital/Financing Update (CAP), as it concerns company fundraising and capital structure changes through stock incentives.
2023-08-23 Chinese
长春百克生物科技股份公司关于向2022年限制性股票激励计划激励对象授予预留部分限制性股票的公告
Share Issue/Capital Change Classification · 95% confidence The document is an official announcement from Changchun Baike Biotechnology Co., Ltd. regarding the reserved grant of restricted stock under the 2022 restricted stock incentive plan. It details the grant date, number of shares, price, approval procedures, legal and independent opinions, and accounting treatment of the stock incentive plan. The content focuses on the company's stock incentive plan implementation and related approvals rather than financial results or management changes. It is not a full annual or interim report, audit report, earnings release, or management discussion. It is a formal announcement about a capital change related to stock incentives (restricted stock grants). Therefore, the document fits best under the category of Share Issue/Capital Change (SHA). The document length and detail confirm it is the announcement itself, not a brief notice or a report publication announcement.
2023-08-23 Chinese
长春百克生物科技股份公司关于首次公开发行股票部分募投项目结项并将节余募集资金永久补充流动资金的公告
Capital/Financing Update Classification · 95% confidence The document is an official announcement from Changchun Baike Biotechnology Co., Ltd. regarding the completion of a portion of its initial public offering (IPO) fundraising projects and the permanent allocation of surplus raised funds to working capital. It details the fundraising amounts, project investment status, surplus funds, and approvals from the board, supervisory committee, independent directors, and the sponsoring institution. The document is a formal disclosure about the use and reallocation of IPO proceeds, not a financial report or earnings release. It does not contain financial statements or detailed financial analysis but focuses on the status and management of capital raised through the IPO. This fits the category of Capital/Financing Update (CAP), as it updates on the company's fundraising project completion and capital usage.
2023-08-23 Chinese
长春百克生物科技股份公司监事会关于公司2022年限制性股票激励计划预留授予激励对象名单的核查意见（截止预留授予日）
Regulatory Filings
2023-08-23 Chinese
北京植德律师事务所关于长春百克生物科技股份公司2022年限制性股票激励计划预留授予及作废部分预留限制性股票相关事项的法律意见书
Regulatory Filings
2023-08-23 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.